STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas
Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today
announces that the Annual Report for 2020 now is available at the
company's website: www.calliditas.com.
This information is information that Calliditas Therapeutics
AB is obliged to make public pursuant to the Securities Markets
Act. The information was submitted for publication at 14:30 CET on April 27,
2021.
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
About Calliditas
Calliditas Therapeutics is a biopharma company based in
Stockholm, Sweden focused on
identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product candidate, Nefecon, is a proprietary, novel oral
formulation of budesonide, an established, highly potent local
immunosuppressant, for the treatment of the autoimmune renal
disease IgA nephropathy, or IgAN, for which there is a high unmet
medical need and there are no approved treatments. Calliditas is
running a global Phase 3 study within IgAN and, if approved, aims
to commercialize Nefecon in the United
States. Calliditas is listed on Nasdaq Stockholm (ticker:
CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit
www.calliditas.com for further information.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics--2020-annual-report-published,c3334502
The following files are available for download:
https://mb.cision.com/Main/16574/3334502/1408150.pdf
|
Calliditas AR
2020_EN_
|
https://mb.cision.com/Public/16574/3334502/83e78aaa2310d2ec.pdf
|
Annual report 2020
published EN
|
View original
content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-2020-annual-report-published-301277937.html
SOURCE Calliditas Therapeutics